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Background: Rotavirus infection is a major cause of childhood diarrhea in Libya. The objective of this study is
to evaluate the cost-effectiveness of rotavirus vaccination in that country.
Methods: We used a published decision tree model that has been adapted to the Libyan situation to analyze
a birth cohort of 160,000 children. The evaluation of diarrhea events in three public hospitals helped to
estimate the rotavirus burden. The economic analysis was done from two perspectives: health care provider
and societal. Univariate sensitivity analyses were conducted to assess uncertainty in some values of the
variables selected.
Results: The three hospitals received 545 diarrhea patients aged55 with 311 (57%) rotavirus positive test
results during a 9-month period. The societal cost for treatment of a case of rotavirus diarrhea was estimated
at US$ 661/event. The incremental cost-effectiveness ratio with a vaccine price of US$ 27 per course was
US$ 8,972 per quality-adjusted life year gained from the health care perspective. From a societal perspective,
the analysis shows cost savings of around US$ 16 per child.
Conclusion: The model shows that rotavirus vaccination could be economically a very attractive intervention
in Libya.
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R
otavirus is an important cause of diarrhea in
children, with globally more than 110 million
cases, 2 million hospitalizations, 25 million out-
patient visits, and 450,000 deaths annually. The incidence
rate of rotavirus infection is often similar in developing
and developed countries. Meanwhile, the mortality rate is
much higher in the developing than in the developed
world, as more than 80% of all the rotavirus deaths occur
in the developing countries (16). The disease is mani-
fested by watery diarrhea causing severe dehydration.
As the virus destroys intestinal villi, the diarrhea may
stop only when the villi have regenerated. The disease
may lead to hospitalization and even death. During
epidemic seasons, rotavirus is responsible for about 20
40% of all hospital admissions and 20% of the diarrhea
deaths (6). These percentages were recently confirmed
for Libya (7, 8). Adequate rehydration is the therapeutic
strategy against the disease, but it does not affect disease
spread. This diarrhea poses a high economic burden on
the health care system and on the families because of the
high hospitalization and medical costs and because of
work absenteeism of family members who normally care
for the children (912).
Two safe and effective rotavirus vaccines on the
global market, available since the end of 2005, can pre-
vent diarrhea events in young children by more than
80% (1318). These two vaccines against rotavirus infec-
tion have also been licensed in Libya. One is a two-dose
vaccine, called Rotarix† (GlaxoSmithKline, Biologicals,
Rixensart, Belgium), which can be given at the age of 2 and
4 months, and the other is a three-dose vaccine, called
RotaTeq† (Merck, Whitehouse Station, NJ, USA), which
can be given at 2, 4, and 6 months (15, 18). Introduction
of the rotavirus vaccine into the National Immunization
Program (NIP) of Libya could prevent many diarrhea
events in children and may offset much of the health care
cost (1921). In Libya, the disease leads to a massive use
of public hospital services, which provide free treatment.
This study assessed the cost-effectiveness of introducing
the rotavirus vaccine into the NIP in Libya. We present
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theoretical modeling results with best estimates to measure
the cost-effectiveness of the vaccine using a Libyan cohort,
age 55. The findings may support the decision of admin-
istering rotavirus vaccination into the NIP. We considered
two different perspectives for the analysis. One is the health
care system and the other is societal, including all the
different cost items in the equation.
Subjects and methods
This is a theoretical modeling study that helps to define
the economic value of rotavirus vaccination in Libya. We
used the available country-specific data whenever possi-
ble. In the absence of country-specific data, assumptions
were made. These assumptions were tested in sensiti-
vity analysis. In the next paragraphs, we present the data
collected at the national level, describe the model used,
and present the assumptions put forth in the model. We
also define the sensitivity analysis that was undertaken.
Data collection
We collected data during the period from August 2012
to April 2013 (9 months) to determine the proportion
of rotavirus cases among children with diarrhea aged 55
in three public hospitals of two cities, Zliten and Khoms,
located in the north-western part of Libya. Stool samples
were collected from suspected cases in hospital care and
in outpatient clinics to test for rotavirus. A suspected case
was defined as a child aged 55 with episodes of diarrheal
illness (loose stools more than three times a day) (18, 22).
Once the sample was taken by the nurse, it was stored
in a fridge at the hospital, and collected samples were
transported once a week to the National Laboratory by
car in fridge boxes. The samples were analyzed at the
National Laboratory because the relevant tests were not
routinely performed at the study hospitals. To identify
rotavirus infections (group A), we used an immunoassay
kit ProSpect Rotavirus Test (Oxoid Ltd, UK). The kit
was provided by the World Health Organization, which
also provided training for the laboratory staff on how to
use the test.
Cost items
The confirmed rotavirus cases in the hospital setting
were used to estimate the hospitalization cost and the
indirect cost paid by parents. Since public hospitals
provide health services free of charge, the overall cost for
treating diarrhea is poorly documented because there are
no bills of payment to refer to. We estimated the hospital
cost by including the bed-day cost, the drug cost, and the
laboratory test cost during hospitalization. The bed-day
cost was estimated from staff salary, furniture, equipment,
food, laundry, disposal, cleaning, utilities, and mainte-
nance. Details of drugs and laboratory tests administered
to the patients were retrieved from the patient files, and
their costs were obtained from the central pharmacy and
the main laboratory at the hospital, respectively. Details
of the expenditure involved were also collected from
the pediatric ward in the year 2012. Furthermore, the
total number of bed-days at the pediatric ward in 2012
was considered to determine the cost per bed-day. Cost
per consultation of the general practitioner and that of
the pediatrician in the outpatient clinic was determined
according to expert opinion (23). Rate of inflation in
Libya was obtained from the World Bank [4.7%, (24)].
It was used to estimate the current cost of treatment of a
rotavirus patient.
Details of indirect cost was collected from interviews
with the parents (n130). When a child was discharged
from hospital care or from an outpatient clinic, each
parent was asked to participate in an interview about all
the costs they incurred due to the disease. The interview
was voluntary and involved no payment. Each interview
took about 15 min, and the same person interviewed all
the participants. The information collected consisted of
transportation cost from home to the medical or hospital
and back, household cost, which included the extra cost
families have when relatives and friends come to visit in
order to provide support. These visits necessitate provi-
sion of food and beverages. Moreover, there is loss of
income due to absence from work during the illness.
The model
A simple disease-specific decision tree model was used
to assess the cost-effectiveness of rotavirus vaccination for
a birth cohort estimated at 160,000 children. The model
was developed in MS Excel and has already been published
for the economic assessment of rotavirus vaccination in
other countries, including Turkey (25). The model com-
pares two theoretical situations of non-vaccinated and
vaccinated children during the risk period from birth to
the age of 5. It subdivides the disease condition into
four health states: mild (staying home), moderate (seeking
medical advice), severe (being hospitalized), and death.
The model was selected because it is easy to use, trans-
parent, and has a limited number of variables to work with
(n20). The model also allows performing sensitivity
analysis and budget impact estimates. The outcome is
close to the more extended Markov cohort models that
are more precise in some aspects of the vaccine impact
related to vaccine compliance and completion (25).
Cost-effectiveness calculation
The cost for the rotavirus vaccine is presented as a
condition for being cost-effective. It included the cost of
the vaccine with the cost of administration per child and
per full course. Vaccine administration cost was estimated
considering the cost for staff, training, and transporta-
tion related to the rotavirus vaccine. Cold chain cost was
excluded since rotavirus vaccine could utilize the same
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storage used for other vaccines. The vaccine coverage rate
is assumed to be the same as for the DPT vaccine in 2013,
which was estimated at 98% for a three-dose vaccine
because rotavirus vaccination can be given at the same
age together with the DPT vaccine (26).
The model is used to evaluate under baseline conditions
the effect of the vaccine on any rotavirus diarrhea event,
medical visits, hospitalizations, and deaths. In addition,
the model allows calculation of the cost-effectiveness
of rotavirus vaccination when introduced into the NIP
by comparing non-vaccinated and vaccinated situations.
The model does this from different perspectives. One
perspective is the health care system, where only the cost
incurred by that institution is considered, and the other is
the societal situation, which includes all costs from
whatever source. The rate of rotavirus diarrhea in the birth
cohort of 55 years old is based on the definition of
diarrhea as set by the WHO criteria. The rates of medical
visits and hospitalizations of the birth cohort were
assumed based on literature review as well as on the deaths
reported due to rotavirus in the birth cohort (7). Finally,
we introduced a quality-adjusted life years (QALY)
assessment per health state in the model equivalent to
the one used in the Turkish model (25). The QALYs gained
from avoiding cause-specific deaths is based on the life
expectancy at birth for Libya (27). QALYs were selected
here as we could easily refer to the reported literature
on how QALYs were estimated for each health state in the
model. The incremental cost-effectiveness ratio (ICER)
was calculated per QALY gained, as well as per diarrhea
event avoided, death avoided, hospitalization avoided,
and medical visit avoided.
Sensitivity analysis
An extended univariate sensitivity analysis was performed
on the key variables in the model assuming a range testing
of 20% change (above and under) in order to identify
the robustness of the ICER result. A 20% change should
be able to identify a more meaningful value change for
some of the variables selected. This is certainly the case
when the baseline value such as vaccine efficacy has a
high starting value. The results are presented as a tornado
diagram of the 15 most influential variables considered
separately from a health provider and from a societal
perspective.
Approval
Approval for the study was given by the University of
Malaya Medical Ethics Committee (IRP 908.6). Health
authorities in the places of the study and National Center
for Disease Control (NCDC) provided the permissions to




During the 9 months of data collection at the three
hospitals, there were 545 cases of diarrhea in children
aged 55, of which 311 were due to rotavirus (57%). Most
of the rotavirus cases were inpatient (77%). No deaths
due to rotavirus diarrhea occurred at the hospitals during
that period. The proportion of rotavirus diarrhea in each
hospital and for inpatient and outpatient is presented in
Table 1.
Costs
Total treatment cost for a rotavirus patient was esti-
mated from hospitalization and patient data (Table 2).
The average treatment cost for a rotavirus case was
estimated at US$ 661. The provider cost was US$ 475,
representing 72% of all the cost, while the contribution of
patient cost was US$ 186 (28%). The per diem (bed-day
cost) was the highest cost item (50%), while the lowest
cost item (5%) was the laboratory test. The analysis also
indicates that all the cost data are much skewed, with
big outliers to the right when we look in particular at the
upper range values in Table 2. The average duration for
hospital stay is around 3.02 days.
The household cost includes the cost of extra diapers
and specific hygienic items for the child, as well as the
hospitality cost for relatives or friends visiting due the
child’s illness.
Overall data input
The required variables with their baseline values for
measuring the effect and the cost-effectiveness of rota-
virus vaccination in children using the model are shown
in Table 3.
For 25 values (highlighted in the table), a mini-
mum and a maximum estimate were calculated based








Zliten city 281 167 59
Khoms city 264 144 55
Hospitals 410 (75%) 239 (77%) 58
Outpatient clinic 135 (25%) 72 (23%) 53
Total number 545 311 57
Male 315 179 57
Female 230 132 57
0B1 years old 336 175 52
1B2 years old 142 91 64
2B3 years old 46 33 72
3B4 years old 10 6 60
455 years old 11 6 55
Cost-effectiveness analysis of rotavirus vaccination
Citation: Libyan J Med 2014, 9: 26236 - http://dx.doi.org/10.3402/ljm.v9.26236 3
(page number not for citation purpose)
on a 20% value change. These data were used in the
sensitivity analysis.
Outcome and offsets
The effect of rotavirus vaccination and the cost analysis
measured by the model for one cohort aged55 is re-
ported in Table 4. Introducing the vaccine would avoid
47,000 diarrhea events with a decrease of 3,400 hospita-
lizations, and 20,100 outpatient visits. Deaths related to
rotavirus infection would be reduced by nine cases.
The model predicts that the universal rotavirus vacci-
nation could offset more than 2 million US$ in direct
medical costs. The highest cost-offset is in hospitaliza-
tions avoided (1.6 million US$) followed by the offset in
medical visits (380,000 US$).
ICER of rotavirus vaccine
The ICER in the base cases is US$ 8,972 per QALY gained.
This is below the Libyan per capita GDP of US$ 10,132
in 2012 (24). Being under that threshold identifies the
new intervention as being highly cost-effective accord-
ing to the WHO’s definition of cost-effectiveness (31, 32).
Similarly, the ICER result per hospitalization avoided is
US$ 642, per outpatient visit avoided is US$ 110, and
per diarrhea event avoided is US$ 47. For each death
avoided the vaccine results in an extra cost of US$ 245,734
(Table 5).
Including indirect cost
Including the indirect cost in the equation will heavily
impact the economic value of the vaccine when consider-
ing the patient perspective. These indirect costs include
three factors: the transport cost to and from the medical
care unit, the household cost, and the loss of produc-
tion. Table 6 reports the impact of each factor on the
total cost of vaccination. As can be seen, it leads to im-
portant savings in the range of 16 US$ per child of the
birth cohort, especially because of the reduction in the
household cost, with more than 2.5 million US$ cost
gain. Under such circumstances, there is benefit for each
family unit to pay for the vaccine because the cost of
transportation plus the household cost is much higher
than the vaccination cost.
Sensitivity analysis
For the health care perspective, we analyzed and tested
the ICER results on many different variables. Figure 1
shows the results presented as a tornado diagram. This
diagram indicates from high to low which variable has
the greatest/smallest impact on the outcome measure as
indicated in the X-axis above. For instance, the highest
impact on the ICER result, as expected, is the vaccine
price. The discount factor that takes into account the
value decrease of the QALY per year (equivalent to the
inflation rate) heavily impacts the QALY result on life
expectancy. It is the next impact driver on the ICER result.
The blue color indicates that a lower value for the variable
is selected than the baseline. The red color indicates a
higher value. So, the lower the price of the vaccine, the
lower will be the ICER result. In contrast is the red color
of death cases (the third variable). If that value is in red
color (higher), the ICER result will decrease because there
are more deaths to be avoided and therefore more benefit
to be expected.
The sensitivity analysis for the societal perspective is
analyzed on a different outcome measure than the ICER,
because from the overall analysis in Table 6, we observed
important cost savings. So the outcome measure selected
is a cost difference and not an ICER result. Figure 2
presents the tornado diagram. Surprisingly, the cost of
the vaccine is no longer the first driver of the analysis.
Instead, the prevalence of the disease, the vaccine cover-
age rate, and the cost incurred by a household are the
big influencing factors. There is a clear difference in
what matters most depending on whether one considers
a narrow perspective (health provider only) or a broader
view (society as a whole).
Discussion
This study aimed to evaluate the economic value of
rotavirus vaccination in Libya from the healthcare provi-
ders’ perspective and from a societal perspective. Given the
limited available data to estimate the disease burden,
interpolation of data from various sources, with several
assumptions, had to be made to perform the cost-
effectiveness analysis. A simple decision tree model was
selected to calculate the ICER for a group of children
aged55.
The percentage of diarrhea cases in children in three
major hospitals in Libya attributable to rotavirus infection
was 57%. This is similar to many studies conducted in
other countries, such as Oman (70%) and Iran (58%) (7).
Table 2. Cost of rotavirus treatment among children aged55
Cost (US$)
Variable Mean SD Range Median
Provider cost
Per diem 332.69 (50%) 254.04 682,045 284
Medication 108.61 (16%) 226.26 153,284 66
Laboratory tests 33.94 (5%) 12.41 16108 32
Patient cost
Transportation 74.012 (11%) 80.27 10912 60
Household 70.99 (11%) 80.52 19557 30
Lost income
(indirect cost)
40.68 (6%) 152.96 01,440 0
Total cost per patient 660.92 580.31 1416,389 623
These costs were estimated in 2012 and adjusted with an annual
inflation rate of 4.7% to 2014; SDstandard deviation.
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Cost of rotavirus diarrhea treatment was collected pri-
marily from the patients who sought treatment for ro-
tavirus infection. These were a good approximation of
the true cost incurred for the disease treatment. In this
study, treatment cost for rotavirus disease was US$ 661
per patient, which is similar to that reported in Algeria
(US$ 650) (33). It is lower than that in Belgium (US$
1,005), Norway (US$ 2,382), and Portugal (US$ 2,172),
but much higher than that in Egypt (US$ 19), Vietnam
(US$ 20), and Brazil (US$ 200) (11, 12, 33). Using the same
coverage rate of DPT as for rotavirus vaccine of 98%,
(26, 34), the model showed a large reduction in rotavirus
infection of 47,040 for the birth cohort. This may offset
2 million US$ in direct treatment cost. The ICER per
event avoided was US$ 47, but per QALY gained it was
US$ 8,972. Both values are below the Libyan per capita
GDP of US$ 10,132 in 2012 (24). If we accept that the
GDP per capita is the appropriate threshold for being
cost-effective, we can say that the vaccine is good value
for money, and that rotavirus vaccination is highly cost-
effective using the WHO criteria for an intervention, and
below the Libyan GDP per capita in 2012 (31, 32, 35).
Similarly, the rotavirus vaccine was highly cost-effective
in many countries, such as Vietnam, Indonesia, and Japan
(3638). In other countries, such as the Latin American
countries, Thailand, and the Caribbean, rotavirus vaccina-
tion could also be cost-effective should the price of the
vaccine be lower (39, 40). Most studies showed through
sensitivity analysis that the price of rotavirus vaccine is
a big driver of the cost-effectiveness result (39). Also, in
Table 3. Input variables for estimating the cost-effectiveness of rotavirus vaccination with baseline, minimum (Min), and
maximum (Max) values
Variables Baseline Min Max Source
Annual birth cohort 160,000 (28)
Vaccination coverage rate 98% 78% 100% (26)
Inflation rate 4.7% 3.8% 5.6% (24)
Cost per consultation GP (US$) 15 Local expert opinion
Cost per consultation pediatrician (US$) 29 Local expert opinion
Proportion going to the GP 70% (7)
Cost for medical visit (US$) 15*0.729*0.319.2 15.4 23.0 Calculated
Cost of prescribed drugs (US$) 108.61 This study
Cost for hospital day care (US$) 332.69 This study
Cost for lab test (US$) 33.94 This study
Cost hospitalization (US$) 108.61332.6933.94475.24 380 570 Calculated
Cost labor woman per day (US$) 34 27.2 40.8 This study
Proportion working mothers 35% 28% 42% (29)
Days lost mild 3 2.4 3.6 (7)
Days lost moderate 1 0.8 1.2 (7)
Days lost severe 3 2.4 3.6 (7)
Cost indirect loss mild/event (US$) 34*3*0.3536 Calculated
Cost indirect loss moderate/event (US$) 34*1*0.3512 Calculated
Cost indirect loss severe/event (US$) 34*3*0.3536 Calculated
Cost for transportation severe (US$) 74 59.2 88.8 This study
Cost for household (US$) 70.99 56.8 85.2 This study
Cost vaccine per course (US$) 27 21.60 32.40 This study
Disutility mild 0.00016 0.00013 0.00020 (25)
Disutility moderate 0.00068 0.00055 0.00082 (25)
Disutility severe 0.00575 0.00460 0.00690 (25)
Life expectancy 75 60 90 (27)
Proportion mild 40% 32% 48% (23)
Proportion moderate 15.1% 12.1% 18.1% Local expert opinion
Proportion severe 2.44% 2% 2.9% Local expert opinion
Proportion deaths 0.0055% 0.0044% 0.0066% (7)
Vaccine efficacy against mild 75% 60% 90% (30)
Vaccine efficacy against moderate 85% 68% 100% (30)
Vaccine efficacy against severe 90% 72% 100% (30)
Vaccine efficacy against death 100% 80% 100% (30)
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Belgium, France, Ireland, England, and Wales, the cost-
effectiveness of rotavirus vaccination was sensitive to the
assumption of the vaccine price (4144).
The findings from this analysis provide evidence for
the expected benefit of the introduction of the rotavirus
vaccine in Libya. Generalization of the findings related
to the estimate of the disease burden has to be made
with caution because the study was hospital based and
cases of mild rotavirus infection in the population were
not captured. The vaccine will avoid the latter cases and
therefore improve the economic results. Real-life condi-
tions will see a dramatic reduction in hospitalizations
within the first 2 years after the introduction of the vaccine,
with a high uptake because of the herd effect it will
cause. The use of the model with imputation of some
data from the literature helped to provide a sensitive
estimate. But the ICER of rotavirus vaccination shows
that it is highly cost-effective. Hence, the decision to
incorporate the vaccine into the NIP of Libya is justified,
and priority should be given to continuing allocation
of a budget for this preventive program.
One limitation of this study is that it does not capture
the total burden of the disease in the analysis. Another
is that many assumptions had to be introduced in the
model to keep it running. A more complete epidemiologic
analysis of the disease burden would have helped under-
standing the management of the disease in the whole
country, including remote areas.
An additional part of the study that is not presented
in other cost-effectiveness analyses reported for that
region is the collection of data on money spent on visits
by relatives and neighbors who come to provide support
during the stressful situation. During those visits, the
cost incurred on drinks and cookies negatively impact
the budgets of the families, which are already reeling under
the cost of treatment. Those household costs were
estimated here at 71 US$ per event, which is much higher
than the vaccination cost (see Table 3). This part of
household cost has been underreported in the literature
Table 4. Health outcomes and cost of treatment of rotavirus
patients in no vaccination and vaccination scenarios
Variable No vaccination Vaccination Difference
Efficacy of rotavirus
vaccination
No. No. No. (%)
Birth cohort 160,000 160,000
Rotavirus diarrhea
events
64,000 16,960 47,040 (74)
Outpatient visits 24,160 4,035 20,105 (83)
Rotavirus diarrhea
hospitalization
3,904 461 3,443 (88)
Rotavirus-related
deaths










Vaccine costs  4,233,600 4,233,600
Outpatient visit 463,872 77,467 386,405









Severe condition 22.46 2.65 19.8
Deaths 205.2 0 205.2
Total 254.7 8.20 246
Table 5. Incremental cost-effectiveness analysis of rotavirus
vaccination
Variables NV V Difference ICER (US$)
Incremental cost/QALY
Cost (US$) 14.49 28.31 13.82
QALYs 0.00159 0.00005 0.00154 8,972
Incremental cost/death avoided
Cost (US$) 14.49 28.31 13.82
Deaths 0.000056 0 0.000056 245,734
Incremental cost/hospitalization avoided
Cost (US$) 14.49 28.31 13.82
Hospitalization 0.0244 0.0029 0.0215 642
Incremental cost/outpatient visit avoided
Cost (US$) 14.49 28.31 13.82
Outpatient visit 0.151 0.0252 0.1257 110
Incremental cost/diarrhea event avoided
Cost (US$) 14.49 28.31 13.82
Diarrhea event 0.400 0.106 0.294 47
NVno vaccination; Vvaccination; ICERincremental cost-
effectiveness ratio; QALYquality-adjusted life year.
Table 6. Including the indirect cost (US$) in the economic
evaluation of the vaccine
Cost type NV V Difference
Transport cost (US$) 288,896 158,893 130,003
Household cost (US$) 6,535,623 3,978,223 2,557,401
Productivity loss (US$) 2,711,677 1,669,970 1,041,707
Direct medical cost (US$) 2,318,272 3,446,646 1,128,374
Total cost (US$) 11,854,468 9,253,732 2,600,736
Total cost/child (US$) 74.09 57.83 16.25
NVno vaccination; Vvaccination.
Salem Alkoshi et al.
6
(page number not for citation purpose)
Citation: Libyan J Med 2014, 9: 26236 - http://dx.doi.org/10.3402/ljm.v9.26236
and is not included in economic evaluations of the vaccine.
Vaccination could help saving the family some money.
Moreover, those visits are a means for spreading the dis-
ease. So, there are at least two hidden reasons of additional
benefit by introducing the vaccine: an important reduc-
tion in social cost burden for the parents and the limitation
of the spread of the virus.
Conclusion
Rotavirus infection represents 57% of hospital treated
diarrhea in Libyan children aged 55. Introduction of
rotavirus vaccination is expected to alleviate a signifi-
cant burden of the disease and is highly cost-effective in
Libya. The decision by the government to incorporate
this vaccine into the NIP is justified.
Fig. 1. Sensitivity analysis (tornado diagram) of the incremental cost per QALY gained analyzed from the health provider
perspective (example: the lower the cost of the vaccine, blue color, the lower the cost-effectiveness result; the color changes at the
baseline value of $8,972, see Table 5).
Fig. 2. Sensitivity analysis (tornado diagram) on the cost difference per child in the birth cohort (Vaccination  No Vaccination)
analyzed from a societal perspective (example: the lower the proportion of mild disease, blue color, the lower the cost savings on
the X-axis).
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